Novel Tuberculosis Vaccine Falls Short of Standard BCG in Phase III Trial

Source Summary

An investigational tuberculosis vaccine failed to outperform the standard bacillus Calmette-Guérin (BCG) vaccine in preventing infections among nearly 6,900 newborns in a multicenter phase III trial.